Arming an Oncolytic Herpes Simplex Virus Type 1 With a Single Chain Fragment Variable Antibody Against PD-1 for Experimental Glioblastoma Therapy.

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2311
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 With Integrin Β1 Blocking Antibody OS2966

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Antiviral Effects of Blackberry Extract Against Herpes Simplex Virus Type 1

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology
2011English

Protective Antibody Therapy Is Associated With Reduced Chemokine Transcripts in Herpes Simplex Virus Type 1 Corneal Infection.

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
1996English

Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy

Oncolytic Virotherapy
2018English

A Humanized Single-Chain Variable Fragment Antibody Against Beta3 Integrin inEscherichia Coli

Hybridoma
2011English

Experimental Herpes Simplex Virus Type 1 Encephalitis: Treatment With 5-Trifluoromethyl-2'-Deoxyuridine

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1977English

Development of a New Fusion-Enhanced Oncolytic Immunotherapy Platform Based on Herpes Simplex Virus Type 1

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Functional Recombinant Single‑chain Variable Fragment Antibody Against Agkistrodon Acutus Venom

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2019English

Ribonucleotide Reductase of Herpes Simplex Virus Type 2 Resembles That of Herpes Simplex Virus Type 1.

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
1984English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy